GleamWall
中文EN

BCYC BICYCLE THERAPEUTICS PLC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1761612 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY194.7%
TTM net income YoY43.4%
TTM EPS YoY43.9%
Revenue 3-yr CAGR49.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-189.4%
Net margin-169.8%
FCF margin-211.9%
EBITDA margin-183.8%

Returns

ROE-25.2%
ROA-21.3%
ROIC (approx.)-4,542.9%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets10.9%
Debt / equity0.00x
Current ratio12.09x
Interest coverage-815.60x

Cash quality & payout

Operating cash flow / net income1.24x
Accruals ratio5.0%
Payout ratio—
Capex / revenue2.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$34.06M$629,000$887,000$47.95M$11.73M$2.92M$9.98M$3.71M
R&D expense$33.42M$41.16M$48.90M$51.77M$58.43M$71.03M$59.06M$49.78M
SG&A expense$14.11M$14.03M$17.47M$20.89M$18.86M$18.49M$21.12M$21.59M
Operating income-$13.48M-$54.56M-$65.48M-$24.71M-$65.55M-$86.60M-$70.20M-$67.66M
Interest expense$45,000$44,000$48,000$57,000$44,000$54,000$51,000$52,000
Pretax income-$9.31M-$50.24M-$60.65M-$18.89M-$58.90M-$79.18M-$61.84M-$52.94M
Income tax$1.17M$90,000$172,000$1.26M$205,000-$231,000-$1.09M-$1.08M
Net income-$10.48M-$50.33M-$60.83M-$20.15M-$59.10M-$78.95M-$60.75M-$51.85M
EBITDA-$12.38M-$53.46M-$64.35M-$23.37M-$63.75M-$84.90M-$68.57M-$65.96M
EPS (basic)-0.15-0.72-0.87—-0.85-1.14-0.88—
EPS (diluted)-0.15-0.72-0.87—-0.85-1.14-0.88—
Dividends declared per share0.000.000.000.000.000.000.000.00
Weighted avg. shares (diluted)69.98M69.80M69.68M—69.30M69.25M69.20M—
Balance sheet
Cash & equivalents$469.93M$510.05M$559.47M$628.11M$648.33M$721.45M$792.97M$880.07M
Receivables———$0——$136,000$0
Current assets$537.56M$575.24M$619.13M$682.88M$738.82M$804.26M$856.09M$928.61M
PP&E, net$4.21M$4.70M$5.73M$6.02M$6.86M$8.31M$8.74M$9.52M
Total assets$567.18M$606.58M$652.40M$717.60M$763.95M$832.18M$883.89M$956.87M
Current liabilities$44.46M$47.63M$48.89M$56.98M$69.28M$77.42M$57.62M$67.23M
Total liabilities$61.90M$96.32M$98.08M$107.62M$145.47M$163.27M$143.56M$163.81M
Shareholders' equity$505.28M$510.25M$554.32M$609.98M$618.48M$668.91M$740.33M$793.06M
Shares outstanding69.99M69.81M69.71M69.37M69.31M69.25M69.20M69.06M
Cash flow statement
Operating cash flow-$40.30M-$49.61M-$65.92M-$19.35M-$71.17M-$72.79M-$86.37M-$9.40M
Capital expenditure$305,000$265,000$713,000$574,000$674,000$498,000$604,000$368,000
Free cash flow-$40.61M-$49.87M-$66.64M-$19.92M-$71.85M-$73.28M-$86.97M-$9.76M
Investing cash flow-$305,000-$265,000-$713,000-$574,000-$674,000-$498,000-$604,000-$368,000
Financing cash flow-$31,000-$50,000-$54,000-$15,000-$30,000-$45,000-$41,000$203,000
Depreciation & amortization$1.10M$1.10M$1.13M$1.34M$1.80M$1.70M$1.63M$1.70M
Stock-based compensation$5.42M$6.40M$6.93M$11.65M$8.77M$9.44M$9.61M$10.33M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.